-
TRANSIL High Sensitivity Binding Kit, 1 ul Lipid Content - Vials
TRANSIL High Sensitivity Binding Kit, 1 ul Lipid Content - Vials
- 中文名称：
- TRANSIL High Sensitivity Binding Kit, 1 ul Lipid Content - Vials
- 英文名称：
- TRANSIL High Sensitivity Binding Kit, 1 ul Lipid Content - Vials
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA60732
- 规格：
- 0.01 mL|0.003 mL|0.025 mL|2x0.025 mL|3x0.025 mL
- 保存建议：
- 储存在-20摄氏度
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- N/A
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Background: The plasma protein binding of drugs continues to be important for property pharmacokinetic evaluations and in routine clinical monitoring of drugs. This is because for many drugs, the therapeutic and toxic response correlates better with the concentration of diffusible, unbound drug than with the total drug concentration. Several methods exist for assessing the unbound fraction of drug in plasma. Standard methods include dialysis, ultrafiltration, centrifugation and rapid dialysis with immobilized plasma proteins (TRANSIL HSA and AGP Binding kit). These methods differ in their limitations and are typically used as complimentary tools to assess the unbound fraction for a wide array of chemical structures. However, if the unbound fraction becomes very low and comprises only 1% of the total drug in plasma or even less, then all the mentioned methods become inaccurate mainly because of analytical problems. Plasma dilution can be used to increase the unbound fraction, however, care needs to be taken not to saturate the binding sites of the binding proteins in plasma that have only a very low abundance, such as a1-acid glycoprotein, lipoproteins, or sex hormone binding protein. Another problem that typically arises with highly lipophilic drugs is a deteriorating recovery of drugs in the experiment due to non-specific binding. The erythrocyte partitioning assay was developed to circumvent both the analytical problem and the problem on nonspecific binding (Tucker et al. 1970, Trung et al. 1984, Urien et al 1990). This assay assesses plasma protein binding through competitive binding to cell membranes from erythrocytes. Originally the erythrocyte partitioning assay was performed with erythrocytes from the same species as the plasma proteins. It turned out the assay's accuracy is not compromised when using human erythrocytes (Schuhmacher et al., 2000) or TRANSIL beads with immobilized membranes (Schuhmacher et al., 2004). Hence, the assay can be simplified and the cumbersome steps of washing and handling of erythrocytes can be eliminated altogether.
Principle of the Assay: The TRANSIL High Sensitivity Binding assay determines the fraction of drug bound to plasma indirectly by determining the partitioning of drug between a plasma phase and a lipid membrane phase. The principle of the assay is equivalent to the erythrocyte partitioning assay (Schuhmacher et al., 2004). The assay assesses plasma protein binding through competitive binding to synthetic cell membranes and has two key principles to obtain accurate binding estimates: (i) the membranes compete with the plasma proteins for finding the drug candidate, hence the more drug shifts away from plasma to membrane, the weaker the protein binding in comparison to the membrane affinity; (ii) the assay assess only the drug concentration in the membrane and the plasma/buffer fraction. A consequence of the latter is that there is no pure buffer phase in which the compound could precipitate and that the assay will not measure the unbound concentration of the drug directly. Assay principle (i) allows the accurate determination of the unbound fraction by measurement of the membrane affinity in different plasma dilutions.
